

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 2, 2025

FITC anti-human CD197 (CCR7)

RRID:AB_10916386

Type: Antibody

Proper Citation

(BioLegend Cat# 353216, RRID:AB_10916386)

Antibody Information

URL: http://antibodyregistry.org/AB_10916386

Proper Citation: (BioLegend Cat# 353216, RRID:AB_10916386)

Target Antigen: CD197

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: FITC anti-human CD197 (CCR7)

Description: This monoclonal targets CD197

Target Organism: human

Clone ID: Clone G043H7

Antibody ID: AB_10916386

Vendor: BioLegend

Catalog Number: 353216

Alternative Catalog Numbers: 353215

Record Creation Time: 20231110T063413+0000

Record Last Update: 20241114T233639+0000

Ratings and Alerts

No rating or validation information has been found for FITC anti-human CD197 (CCR7).

No alerts have been found for FITC anti-human CD197 (CCR7).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 14 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Kirk AM, et al. (2024) DNAJB1-PRKACA fusion neoantigens elicit rare endogenous T cell responses that potentiate cell therapy for fibrolamellar carcinoma. Cell reports. Medicine, 5(3), 101469.

Williams GP, et al. (2023) Unaltered T cell responses to common antigens in individuals with Parkinson's disease. Journal of the neurological sciences, 444, 120510.

Si W, et al. (2023) Design of diversified chimeric antigen receptors through rational module recombination. iScience, 26(4), 106529.

Vyasamneni R, et al. (2023) A universal MHCII technology platform to characterize antigen-specific CD4+ T cells. Cell reports methods, 3(1), 100388.

Pan Q, et al. (2023) Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A*02:01 patients with advanced soft tissue sarcoma. Cell reports. Medicine, 4(8), 101133.

Vanshylla K, et al. (2022) Discovery of ultrapotent broadly neutralizing antibodies from SARS-CoV-2 elite neutralizers. Cell host & microbe, 30(1), 69.

Yu ED, et al. (2022) Development of a T cell-based immunodiagnostic system to effectively distinguish SARS-CoV-2 infection and COVID-19 vaccination status. Cell host & microbe, 30(3), 388.

Mudd PA, et al. (2022) SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans. Cell, 185(4), 603.

Yu ED, et al. (2022) Immunological memory to common cold coronaviruses assessed longitudinally over a three-year period pre-COVID19 pandemic. Cell host & microbe, 30(9), 1269.

Einkauf KB, et al. (2022) Parallel analysis of transcription, integration, and sequence of single HIV-1 proviruses. *Cell*, 185(2), 266.

Zebley CC, et al. (2021) CD19-CAR T cells undergo exhaustion DNA methylation programming in patients with acute lymphoblastic leukemia. *Cell reports*, 37(9), 110079.

Tarke A, et al. (2021) Impact of SARS-CoV-2 variants on the total CD4+ and CD8+ T cell reactivity in infected or vaccinated individuals. *Cell reports. Medicine*, 2(7), 100355.

Hearnden R, et al. (2021) Isolation of stromal vascular fraction cell suspensions from mouse and human adipose tissues for downstream applications. *STAR protocols*, 2(2), 100422.

Fu Y, et al. (2021) CD27-CD38+ B cells accumulated in early HIV infection exhibit transitional profile and promote HIV disease progression. *Cell reports*, 36(2), 109344.